Laboratory of Molecular and Cellular Screening Processes

Laboratory of Molecular and Cellular Screening Processes

 

Acronym: LPCMC
Code: LR19CBS06
Laboratory Director: Prof. Saber MASMOUDI
LPCMC will be in charge of the SEED high throughput sequencing activity. The LPCMC R&D program is based on an integrated approach (integrative biology) that uses and develops molecular, cellular and bioinformatic tools to support the development of new therapeutic molecules and improve diagnosis and authentication. The main objectives of the research programs to be carried out over the next four years are:

– Discovering, testing and producing new treatments

– Developing molecular diagnostic kits and digital enhancement of genomic data

To design and develop suitable treatments, LPCMC masters cell study techniques and molecular modeling tools, which are major assets to accelerate the process of discovery and sorting of therapeutic molecules. An in vivo screening system for zebrafish as an animal model was also implemented during the previous program contract. While our previous screening results for new molecules are encouraging, it must be recognized that the development of a new chemical or molecular drug is a very expensive and time-consuming process. During this program contract, we are also offering complementary approaches that consist of repositioning and improving drugs on the market.

High-throughput molecular technologies have emerged international markets, based first on the development of biochips and later on massive sequencing. The implementation of these techniques in our laboratory has helped to revolutionize the field of human genetics in Tunisia on the one hand by increasing the diagnostic yield and the implementation of new molecular tests and on the other hand by the acceleration of the discovery of new genes responsible for
genetic pathologies. However, the application of these broadband technologies in diagnostics requires overcoming several biological, IT and economic challenges in order to be able to deliver relevant and interpretable results more quickly and at a lower cost.

To achieve its objectives, the laboratory has clinical data and blood samples and biopsies from several hundred patients and families suffering from hereditary diseases, as well as from individuals in the general population. It also has several cell lines and microbial strains for ex-vivo cloning and screening. The skills of LPCMC researchers are complementary, covering key areas such as genomics, proteomics, and bioinformatics. The laboratory has also integrated researchers who have skills in the medical or pharmaceutical field to benefit from their expertise and benefit from their contributions thanks to their familiarization with human disease, therapeutic molecules… Close interaction between researchers and research pharmacists will help optimize the choice and relevance of models and protocols for experimental therapy and integrate new areas of targeted therapy. Similarly, for research that is directly oriented towards the patient with the discovery of new genes and diagnosis, the contribution of medical researchers is more than ever necessary to integrate all the clinical data.